Special Issue "Pharmacogenomics & Mitochondrial Genomics as a Strategy for the Diagnosis & Treatment of PTSD"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Molecular Diagnostics".

Deadline for manuscript submissions: closed (28 February 2021).

Special Issue Editor

Prof. Dr. Gjumrakch Aliev
E-Mail Website
Guest Editor
GALLY International Research Institute, 7733 Louis Pasteur Drive #330, San Antonio, TX 78229, USA
Interests: pharmacogenomics; mitochondrial genomics; mitochondrion and oxidative stress; aging and age-associated diseases; diagnosis and treatment of PTSD

Special Issue Information

Dear Colleagues,

Post-traumatic stress disorder (PTSD) is a mental disorder that appears to develop after exposure to exceptionally threatening or inescapable horrifying events; these traumatic events include severe accidents, emotional/social abuse, physical assault, military combat, or natural disasters. Currently, the number of people diagnosed with PTSD in the United States is 24 million (~8% of Americans), costing $43 billion per year. At this point there are no effective strategies in use for determining a clinical diagnosis, controlling, and/or treating PTSD. Conventional wisdom has decreed that PTSD is a lifelong disorder and all treatment strategies are merely symptomatic, targeting the symptoms but not the exact etiology. The current treatment protocols rarely yield favorable results, and the use of antidepressants, antipsychotics, monoamine oxidase inhibitors (MAOIs), beta-blockers, and benzodiazepines have many undesired side effects and limited effectiveness, further complicating PTSD. These disadvantageous pharmacological and therapeutic characteristics provoke a low adherence to treatment in an important percentage of patients afflicted by PTSD or concomitants caused by PTSD.

The current understanding of PTSD has no sufficient information/understanding to guide research. We have extensively reviewed the clinical research as well as the publication sources that define the current methods to diagnose PTSD and the aforementioned strategies of treatment. We have found an absence of evidence to support their claims. Additionally, research towards the development of an actual diagnosis or treatment protocol is very limited, almost nil. The absence of the ability to distinguish PTSD from other mental disorders is due to the lack of laboratory and clinical biomarkers for determining PTSD as well as the etiopathogenesis that causes PTSD.

The objective of this Special Issue is to put together, from the different research groups, recent findings regarding the implications of pharmacogenomics and mitochondrial genomics to identify specific biomarkers for determining PTSD; this will reveal avenues to use genomic knowledge as a strategy for the adjustment of medications that are used as a basis for treatment, the effectiveness of treatment, and prophylactics. Therefore, future analyses and newly developed protocols will allow for the development of pharmacogenetic profiles to not only appropriately diagnose PTSD but also determine the effectiveness of medications, allowing for the avoidance of undesired side effects or cumulative intoxication by using the correct mitochondrion selective medications at the right dosage for each patient.

I am very pleased to welcoming you to submit full-length original research and review articles to this Special Issue.

Prof. Dr. Gjumrakch Aliev
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Pharmacogenomics
  • Mitochondrial genomics
  • Mitochondrion and oxidative stress
  • Aging and age-associated diseases
  • Diagnosis and treatment of PTSD

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Open AccessReview
Neurophysiology and Psychopathology Underlying PTSD and Recent Insights into the PTSD Therapies—A Comprehensive Review
J. Clin. Med. 2020, 9(9), 2951; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm9092951 - 12 Sep 2020
Cited by 2 | Viewed by 1282
Post-traumatic stress disorder (PTSD) is a well-known psychiatric disorder that affects millions of people worldwide. Pharmacodynamic and cognitive-behavioral therapies (CBT) have been used to treat patients with PTSD. However, it remains unclear whether there are concurrent changes in psychopathological and neurophysiological factors associated [...] Read more.
Post-traumatic stress disorder (PTSD) is a well-known psychiatric disorder that affects millions of people worldwide. Pharmacodynamic and cognitive-behavioral therapies (CBT) have been used to treat patients with PTSD. However, it remains unclear whether there are concurrent changes in psychopathological and neurophysiological factors associated with PTSD patients. Past reports described those PTSD patients with efficient fatty acid metabolism, neurogenesis, mitochondrial energy balance could improve ability to cope against the conditioned fear responses and traumatic memories. Furthermore, cognitive, behavioral, cellular, and molecular evidence can be combined to create personalized therapies for PTSD sufferers either with or without comorbidities such as depression or memory impairment. Unfortunately, there is still evidence lacking to establish a full understanding of the underlying neurophysiological and psychopathological aspects associated with PTSD. This review has extensively discussed the single nucleotide polymorphism (SNPs) of genetic factors to cause PTSD, the implications of inflammation, neurotransmitter genomics, metabolic alterations, neuroendocrine disturbance (hypothalamus-pituitary-adrenal (HPA) axis), mitochondrial dynamics, neurogenesis, and premature aging related to PTSD-induced psychopathology and neurophysiology. In addition, the review delineated the importance of CBT and several pharmacodynamic therapies to mitigate symptomatology of PTSD. Full article
Show Figures

Graphical abstract

Back to TopTop